Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 5
1999 12
2000 11
2001 14
2002 12
2003 12
2004 12
2005 8
2006 10
2007 10
2008 14
2009 11
2010 13
2011 13
2012 26
2013 26
2014 27
2015 35
2016 36
2017 40
2018 31
2019 40
2020 40
2021 39
2022 24
2023 14
2024 18
2025 7
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Results by year

Filters applied: . Clear all
Page 1
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Boorjian SA, et al. Among authors: bivalacqua tj. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27. Lancet Oncol. 2021. PMID: 33253641 Free PMC article. Clinical Trial.
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Narayan VM, et al. Among authors: bivalacqua tj. J Urol. 2024 Jul;212(1):74-86. doi: 10.1097/JU.0000000000004020. Epub 2024 May 5. J Urol. 2024. PMID: 38704840 Free PMC article. Clinical Trial.
In Reply.
Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. Brennen WN, et al. Among authors: bivalacqua tj. Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. Stem Cells Transl Med. 2019. PMID: 30925030 Free PMC article. No abstract available.
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Tan WS, et al. Among authors: bivalacqua tj. Eur Urol Oncol. 2022 Oct;5(5):505-516. doi: 10.1016/j.euo.2022.05.005. Epub 2022 Jun 17. Eur Urol Oncol. 2022. PMID: 35718695 Review.
Reply by Authors.
Kohn TP, DuComb W, Sury K, Choi U, Bivalacqua TJ. Kohn TP, et al. Among authors: bivalacqua tj. Urol Pract. 2024 May;11(3):516. doi: 10.1097/UPJ.0000000000000551. Epub 2024 Apr 2. Urol Pract. 2024. PMID: 38564802 No abstract available.
Reply by Authors.
Patel SH, Gabrielson AT, Chan S, Schwartz D, Collins C, Singla N, Trock B, Bivalacqua TJ, Hahn N, Kates MR. Patel SH, et al. Among authors: bivalacqua tj. J Urol. 2024 Jul;212(1):103. doi: 10.1097/JU.0000000000004017. Epub 2024 May 7. J Urol. 2024. PMID: 38713596 No abstract available.
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: bivalacqua tj. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821066
Tissue-engineered urinary conduits.
Kates M, Singh A, Matsui H, Steinberg GD, Smith ND, Schoenberg MP, Bivalacqua TJ. Kates M, et al. Among authors: bivalacqua tj. Curr Urol Rep. 2015 Mar;16(3):8. doi: 10.1007/s11934-015-0480-3. Curr Urol Rep. 2015. PMID: 25677229 Review.
468 results